0001103795 2026-01-01 2026-06-30 0001103795 2026-08-07 0001103795 2026-06-30 0001103795 2025-12-31 0001103795 us-gaap:ConvertibleNotesPayableMember 2026-06-30 0001103795 us-gaap:ConvertibleNotesPayableMember 2025-12-31 0001103795 2026-04-01 2026-06-30 0001103795 2025-04-01 2025-06-30 0001103795 2025-01-01 2025-06-30 0001103795 us-gaap:CommonStockMember 2026-03-31 0001103795 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001103795 us-gaap:RetainedEarningsMember 2026-03-31 0001103795 2026-03-31 0001103795 us-gaap:CommonStockMember 2025-12-31 0001103795 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001103795 us-gaap:RetainedEarningsMember 2025-12-31 0001103795 us-gaap:CommonStockMember 2025-03-31 0001103795 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001103795 us-gaap:RetainedEarningsMember 2025-03-31 0001103795 2025-03-31 0001103795 us-gaap:CommonStockMember 2024-12-31 0001103795 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001103795 us-gaap:RetainedEarningsMember 2024-12-31 0001103795 2024-12-31 0001103795 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001103795 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001103795 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001103795 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001103795 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-06-30 0001103795 us-gaap:RetainedEarningsMember 2026-01-01 2026-06-30 0001103795 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001103795 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001103795 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001103795 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001103795 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001103795 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001103795 us-gaap:CommonStockMember 2026-06-30 0001103795 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001103795 us-gaap:RetainedEarningsMember 2026-06-30 0001103795 us-gaap:CommonStockMember 2025-06-30 0001103795 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001103795 us-gaap:RetainedEarningsMember 2025-06-30 0001103795 2025-06-30 0001103795 us-gaap:StockOptionMember 2026-01-01 2026-06-30 0001103795 us-gaap:StockOptionMember 2025-01-01 2025-06-30 0001103795 us-gaap:WarrantMember 2026-01-01 2026-06-30 0001103795 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001103795 us-gaap:ConvertibleDebtMember 2026-01-01 2026-06-30 0001103795 us-gaap:ConvertibleDebtMember 2025-01-01 2025-06-30 0001103795 qsep:FormerExecutiveMember qsep:SeparationAgreementMember 2026-06-30 0001103795 qsep:FormerExecutiveMember qsep:SeparationAgreementMember 2025-12-31 0001103795 qsep:FormerExecutiveMember qsep:SeparationAgreementMember 2026-01-01 2026-06-30 0001103795 us-gaap:ConvertibleNotesPayableMember 2026-01-01 2026-06-30 0001103795 us-gaap:ConvertibleNotesPayableMember qsep:InterestConvertedMember 2026-01-01 2026-06-30 0001103795 us-gaap:ConvertibleNotesPayableMember 2025-12-31 0001103795 us-gaap:ConvertibleNotesPayableMember 2026-01-01 2026-06-30 0001103795 us-gaap:ConvertibleNotesPayableMember 2026-06-30 0001103795 qsep:AOTPrototypesMember 2026-01-01 2026-06-30 0001103795 qsep:AOTPrototypesMember 2025-01-01 2025-06-30 0001103795 qsep:LicenseAgreementsMember qsep:AOT1Amendment2Member 2025-07-31 0001103795 qsep:LicenseAgreementsMember qsep:AOT2Amendment1Member 2025-07-31 0001103795 qsep:LicenseAgreementsMember 2025-07-31 0001103795 qsep:LicenseAgreementsMember 2026-06-30 0001103795 qsep:LicenseAgreementsMember 2025-12-31 0001103795 qsep:LicenseAgreementsMember 2026-01-01 2026-06-30 0001103795 qsep:LicenseAgreementsMember 2025-01-01 2025-06-30 0001103795 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001103795 us-gaap:ConvertibleNotesPayableMember 2026-01-01 2026-06-30 0001103795 us-gaap:ConvertibleNotesPayableMember 2026-06-30 0001103795 srt:MinimumMember us-gaap:ConvertibleNotesPayableMember 2026-01-01 2026-06-30 0001103795 srt:MaximumMember us-gaap:ConvertibleNotesPayableMember 2026-01-01 2026-06-30 0001103795 qsep:ExerciseOfStockOptionsAndWarrantsMember 2026-01-01 2026-06-30 0001103795 srt:MinimumMember qsep:ExerciseOfStockOptionsAndWarrantsMember 2026-06-30 0001103795 srt:MaximumMember qsep:ExerciseOfStockOptionsAndWarrantsMember 2026-06-30 0001103795 qsep:CashlessExerciseOfWarrantsMember 2026-01-01 2026-06-30 0001103795 srt:MinimumMember qsep:CashlessExerciseOfWarrantsMember 2026-01-01 2026-06-30 0001103795 srt:MaximumMember qsep:CashlessExerciseOfWarrantsMember 2026-01-01 2026-06-30 0001103795 us-gaap:CommonStockMember 2026-06-30 0001103795 us-gaap:StockOptionMember 2025-12-31 0001103795 us-gaap:StockOptionMember 2026-01-01 2026-06-30 0001103795 us-gaap:StockOptionMember 2026-06-30 0001103795 us-gaap:StockOptionMember qsep:OptionPrice1Member 2026-06-30 0001103795 us-gaap:StockOptionMember qsep:OptionPrice1Member 2026-01-01 2026-06-30 0001103795 us-gaap:StockOptionMember qsep:OptionPrice2Member 2026-06-30 0001103795 us-gaap:StockOptionMember qsep:OptionPrice2Member 2026-01-01 2026-06-30 0001103795 qsep:MembersOfTheBoardOfDirectorsMember us-gaap:StockOptionMember 2026-01-01 2026-06-30 0001103795 qsep:MembersOfTheBoardOfDirectorsMember srt:ChiefFinancialOfficerMember us-gaap:StockOptionMember 2026-01-01 2026-06-30 0001103795 qsep:MembersOfTheBoardOfDirectorsMember us-gaap:StockOptionMember 2026-06-30 0001103795 qsep:OfficersAndDirectorsMember us-gaap:StockOptionMember 2026-01-01 2026-06-30 0001103795 qsep:CorporateSecretaryMember us-gaap:StockOptionMember 2026-01-01 2026-06-30 0001103795 qsep:CorporateSecretaryMember us-gaap:StockOptionMember 2026-06-30 0001103795 us-gaap:StockOptionMember qsep:IssuedForServicesMember 2026-01-01 2026-06-30 0001103795 srt:MinimumMember us-gaap:StockOptionMember qsep:IssuedForServicesMember 2026-06-30 0001103795 srt:MaximumMember us-gaap:StockOptionMember qsep:IssuedForServicesMember 2026-06-30 0001103795 srt:MinimumMember us-gaap:StockOptionMember qsep:IssuedForServicesMember 2026-01-01 2026-06-30 0001103795 qsep:CorporateSecretaryMember srt:MaximumMember us-gaap:StockOptionMember 2026-01-01 2026-06-30 0001103795 srt:MaximumMember us-gaap:StockOptionMember qsep:IssuedForServicesMember 2026-01-01 2026-06-30 0001103795 us-gaap:StockOptionMember qsep:VestedFairValueOfOptionsMember 2026-01-01 2026-06-30 0001103795 us-gaap:StockOptionMember qsep:IssuedForServicesMember 2025-01-01 2025-06-30 0001103795 us-gaap:WarrantMember 2026-06-30 0001103795 us-gaap:WarrantMember qsep:WarrantsIssuedForServicesMember 2026-01-01 2026-06-30 0001103795 srt:MinimumMember us-gaap:WarrantMember qsep:WarrantsIssuedForServicesMember 2026-06-30 0001103795 srt:MaximumMember us-gaap:WarrantMember qsep:WarrantsIssuedForServicesMember 2026-06-30 0001103795 us-gaap:WarrantMember qsep:IssuedForServicesMember 2026-01-01 2026-06-30 0001103795 srt:MinimumMember us-gaap:WarrantMember qsep:WarrantsIssuedForServicesMember 2026-01-01 2026-06-30 0001103795 srt:MaximumMember us-gaap:WarrantMember qsep:WarrantsIssuedForServicesMember 2026-01-01 2026-06-30 0001103795 qsep:WarrantsMember 2026-01-01 2026-06-30 0001103795 us-gaap:WarrantMember 2025-12-31 0001103795 us-gaap:WarrantMember 2026-01-01 2026-06-30 0001103795 us-gaap:WarrantMember qsep:Warrant1Member 2026-06-30 0001103795 us-gaap:WarrantMember qsep:Warrant1Member 2026-01-01 2026-06-30 0001103795 us-gaap:WarrantMember qsep:Warrant2Member 2026-06-30 0001103795 us-gaap:WarrantMember qsep:Warrant2Member 2026-01-01 2026-06-30 0001103795 qsep:CEOAndCFOMember qsep:EmploymentAgreementMember 2025-02-19 0001103795 qsep:CEOAndCFOMember qsep:EmploymentAgreementMember 2025-01-31 0001103795 qsep:CEOAndCFOMember qsep:EmploymentAgreementMember 2025-01-03 2025-01-31 0001103795 qsep:CEOAndCFOMember qsep:ExecutionOfEquityFinancingMember qsep:EmploymentAgreementMember 2026-06-30 0001103795 qsep:CEOAndCFOMember qsep:RestrictedCommonStockMember qsep:EmploymentAgreementMember 2025-01-01 2025-06-30 0001103795 qsep:CEOAndCFOMember qsep:RestrictedCommonStockMember qsep:EmploymentAgreementMember 2025-06-30 0001103795 qsep:CEOAndCFOMember qsep:RestrictedCommonStock2Member qsep:EmploymentAgreementMember 2025-01-01 2025-06-30 0001103795 qsep:CEOAndCFOMember qsep:RestrictedCommonStock2Member qsep:EmploymentAgreementMember 2025-06-30 0001103795 qsep:CEOAndCFOMember qsep:EmploymentAgreementMember 2025-01-01 2025-06-30 0001103795 qsep:MembersOfTheBoardOfDirectorsMember qsep:CEOAndCFOMember us-gaap:StockOptionMember 2025-01-01 2025-06-30 0001103795 qsep:KyteMember 2026-01-01 2026-06-30 0001103795 qsep:CompensationAgreementsMember 2026-06-30 0001103795 qsep:CompensationAgreementsMember 2025-12-31 0001103795 qsep:CollaborationAgreementMember 2026-01-01 2026-06-30 0001103795 qsep:CollaborationAgreementMember 2026-06-30 0001103795 qsep:OperatingSegmentMember 2026-04-01 2026-06-30 0001103795 qsep:OperatingSegmentMember 2025-04-01 2025-06-30 0001103795 qsep:OperatingSegmentMember 2026-01-01 2026-06-30 0001103795 qsep:OperatingSegmentMember 2025-01-01 2025-06-30 iso4217:USD shares iso4217:USD shares pure qsep:Integer false --12-31 2026 Q2 0001103795

P3Y

P10Y

P3Y

10-Q true 2026-06-30 false 000-29185 QS ENERGY, INC. NV 52-2088326 23902 FM 2978 Tomball TX 77375 775 300-7647 Yes Yes Non-accelerated Filer true false false 565305854

120000

6000

87000

49000

207000

55000

207000

55000

3167000

1337000

1416000

16000

1201000

1116000

1201000

1351000

5705000

5934000

0.001

750000000

564555854

543350596

564557

543351

139486443

136182649

-145549000

-142605000

-5498000

-5879000

207000

55000

2125000

1892000

2860000

11404000

9000

104000

11000

151000

-2134000

-1996000

-2871000

-11555000

29000

143000

73000

258000

-2163000

-2139000

-2944000

-11813000

-0.00

-0.01

-0.03

556762727

495547582

552055120

467026067

550786275

550786

137049214

-143386000

-5789000

284355 285 36715 37000 9118559 9119 837881 847000 166665 167 19833 20000

993000

112000 112000

25000

4200000

4200

415800

420000

-2163000

564555854

564557

139486443

-145549000

-5498000

543350596

543351

136182649

-142605000

-5879000

2733513 2734 220266 223000 14071747 14072 1327928 1342000 199998 200 24800 25000

765000

463000 463000 62000 62000

25000

4200000

4200

415800

420000

-2944000

564555854

564557

139486443

-145549000

-5498000

483744622

483744

132143256

-136974000

-4347000

22526487 22527 560473 583000 632000 632000 12327405 12328 498672 511000 366663 367 27633 28000

91000

511000

250000

250

47750

48000

-2139000

519215177

519216

134511784

-139113000

-4082000

428424880

428425

121173575

-127300000

-5698000

62804832 62805 2168195 2231000 1430000 1430000 15418805 15419 711581 727000 2016660 2017 96983 99000

6740000

511000

9050000

9050

1441950

1451000

1500000

1500

238500

240000

-11813000

519215177

519216

134511784

-139113000

-4082000

-2944000

-11813000

1290000 6740000

25000

345000

1451000

75000

240000

6000

141000

67000

91000

38000

21000

-54000

182000

118000

-1228000

-2360000

1342000 727000

2285000

-0

24000

1342000

2988000

114000

628000

6000

150000

120000

778000

1600

233000 3803000 25000 99000 0 1430000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">1.</td> <td style="text-align: justify">Description of Business</td></tr> </table> QS Energy, Inc. (“QS Energy”, “Company”) was incorporated on February 18, 1998, as a Nevada Corporation under the name Mandalay Capital Corporation. The Company changed its name to Save the World Air, Inc. on February 11, 1999. Effective August 11, 2015, the Company changed its name to QS Energy, Inc. QS Energy develops and is seeking to commercialize energy efficiency technologies that assist in meeting increasing global energy demands, improving the economics of oil extraction and transport, and reducing greenhouse gas emissions. The Company's intellectual properties include a portfolio of domestic and international patents and patents pending, a substantial portion of which have been developed in conjunction with and exclusively licensed from Temple University of Philadelphia, PA (“Temple”). QS Energy's primary technology is called Applied Oil Technology (AOT), a commercial-grade crude oil pipeline transportation flow-assurance product. AOT is engineered specifically to reduce pipeline pressure loss, increase pipeline flow rate and capacity, and reduce shippers’ reliance on diluents and drag reducing agents to meet pipeline maximum viscosity requirements. AOT is a 100% solid-state system that has shown to reduce crude oil viscosity by applying a high intensity electrical field to crude oil feedstock while in transit. The AOT product is seeking to transition from the testing, research and development stage to initial production for continued testing in advance of our goal of seeking acceptance and adoption by the midstream pipeline marketplace. Basis of Presentation The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 31, 2026. The condensed consolidated balance sheet as of December 31, 2025, included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of the full fiscal year-end results. The accompanying consolidated financial statements of QS Energy Inc. include the accounts of QS Energy Inc. (the Parent) and its wholly owned subsidiaries, QS Energy Pool, Inc. and STWA Asia Pte. Limited. Intercompany transactions and balances have been eliminated in consolidation.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">2.</td> <td style="text-align: justify">Summary of Significant Accounting Policies</td></tr> </table> Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, during the six-months ended June 30, 2026, the Company incurred a net loss of $2,944,000, used cash in operations of $1,228,000 and had a stockholders’ deficit of $5,498,000 as of June 30, 2026. In addition, as of June 30, 2026, 46 notes payable with an aggregate balance of $1,201,000, license agreement payables of $3,167,000 and certain obligations to a former officer are past due. These factors raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025, financial statements, has raised substantial doubt about the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. At June 30, 2026, the Company had cash on hand in the amount of $120,000. Management estimates that the current funds on hand will be sufficient to continue operations through approximately August 2026. Management is currently seeking additional funds, primarily through the issuance of debt and equity securities for cash to operate our business, including without limitation the expenses it will incur in connection with the license agreements with Temple; costs associated with product development and commercialization of the AOT technologies; costs to manufacture and ship the products; costs to design and implement an effective system of internal controls and disclosure of controls and procedures; costs of maintaining our status as a public company by filing periodic reports with the SEC and costs required to protect our intellectual property. In addition, as discussed below, the Company has substantial contractual commitments, including without limitation, certain payments to a former officer and consulting fees, during the remainder of 2026 and beyond. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders in case of equity financing. Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include those related to accruals for potential liabilities, assumptions used in valuing equity instruments issued for financing and services and realization of deferred tax assets, among others. Actual results could differ from those estimates. Basic and Diluted Income (loss) per share Our computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income (loss) per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income (loss) of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. At June 30, 2026 and 2025, we excluded the following dilutive shares as their effect would have been anti-dilutive. <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zp98HEcFljGi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of anti-dilutive shares</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zmatYy5zOCmc" style="width: 13%; text-align: right" title="Anti-dilutive shares">72,462,246</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zGFuaw9eeG7" style="width: 13%; text-align: right" title="Anti-dilutive shares">69,015,001</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zBYEntrvoee2" style="text-align: right" title="Anti-dilutive shares">18,818,413</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTXCbexcFgG5" style="text-align: right" title="Anti-dilutive shares">66,839,512</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Common stock issuable upon conversion of notes payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtMember_zcLB0uTz4J4a" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">14,461,844</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtMember_zXvF1rTmhQx4" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">18,397,839</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630_zZYlajo33HCf" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">105,742,503</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630_zDBfuNAXh9n6" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">154,252,352</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Stock-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. Stock option grants, which are generally time or performance vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods. Research and Development Costs Research and development costs are expensed as incurred, and consist primarily of fees paid to consultants and outside service providers, and other expenses relating to the acquisition, design, development and testing of the Company’s products. Certain research and development activities are incurred under contract. In those instances, research and development costs are charged to operations ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s consolidated balance sheet and then charged to research and development costs in the Company’s consolidated statement of operations as those contract services are performed. For the six-month periods ended June 30, 2026 and 2025 research and development costs were $11,000 and $151,000, respectively. Fair Value of Financial Instruments Accounting standards require certain assets and liabilities to be reported at fair value in the financial statements and provide a framework for establishing that fair value. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation techniques used to measure fair value: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if such data is available without undue cost and effort. The carrying amounts for cash, accounts payable, accrued expenses and convertible notes payable approximate their fair value due to the short-term nature of such instruments. Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. At June 30, 2026 and December 31, 2025, the Company has determined that the warrants issued and outstanding meet the requirements for equity classification. This assessment, which requires the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all of the criteria for equity classification, the warrants are required to be liability-classified and recorded at their initial fair value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants that are liability-classified are recognized as a non-cash gain or loss in the statement of operations at each balance sheet date. At June 30, 2026 and December 31, 2025, the Company did not have any liability-classified warrants. Recent Accounting Pronouncements In November 2024, the FASB issued ASU No. 2024-03 “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” This ASU requires public business entities to disclose, for interim and annual reporting periods, additional information about certain income statement expense categories. The requirements are effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027. Entities are permitted to apply either the prospective or retrospective transition methods. The Company is currently evaluating the impact that the adoption of this ASU will have on its consolidated financial statements. The Company’s management has evaluated all other the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Company’s financial position and results of operations.

Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, during the six-months ended June 30, 2026, the Company incurred a net loss of $2,944,000, used cash in operations of $1,228,000 and had a stockholders’ deficit of $5,498,000 as of June 30, 2026. In addition, as of June 30, 2026, 46 notes payable with an aggregate balance of $1,201,000, license agreement payables of $3,167,000 and certain obligations to a former officer are past due. These factors raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025, financial statements, has raised substantial doubt about the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. At June 30, 2026, the Company had cash on hand in the amount of $120,000. Management estimates that the current funds on hand will be sufficient to continue operations through approximately August 2026. Management is currently seeking additional funds, primarily through the issuance of debt and equity securities for cash to operate our business, including without limitation the expenses it will incur in connection with the license agreements with Temple; costs associated with product development and commercialization of the AOT technologies; costs to manufacture and ship the products; costs to design and implement an effective system of internal controls and disclosure of controls and procedures; costs of maintaining our status as a public company by filing periodic reports with the SEC and costs required to protect our intellectual property. In addition, as discussed below, the Company has substantial contractual commitments, including without limitation, certain payments to a former officer and consulting fees, during the remainder of 2026 and beyond. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders in case of equity financing.

-2944000

-1228000

-5498000

1201000

3167000

120000

Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include those related to accruals for potential liabilities, assumptions used in valuing equity instruments issued for financing and services and realization of deferred tax assets, among others. Actual results could differ from those estimates.

Basic and Diluted Income (loss) per share Our computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income (loss) per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income (loss) of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. At June 30, 2026 and 2025, we excluded the following dilutive shares as their effect would have been anti-dilutive. <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zp98HEcFljGi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of anti-dilutive shares</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zmatYy5zOCmc" style="width: 13%; text-align: right" title="Anti-dilutive shares">72,462,246</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zGFuaw9eeG7" style="width: 13%; text-align: right" title="Anti-dilutive shares">69,015,001</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zBYEntrvoee2" style="text-align: right" title="Anti-dilutive shares">18,818,413</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTXCbexcFgG5" style="text-align: right" title="Anti-dilutive shares">66,839,512</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Common stock issuable upon conversion of notes payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtMember_zcLB0uTz4J4a" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">14,461,844</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtMember_zXvF1rTmhQx4" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">18,397,839</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630_zZYlajo33HCf" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">105,742,503</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630_zDBfuNAXh9n6" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">154,252,352</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zp98HEcFljGi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of anti-dilutive shares</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zmatYy5zOCmc" style="width: 13%; text-align: right" title="Anti-dilutive shares">72,462,246</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zGFuaw9eeG7" style="width: 13%; text-align: right" title="Anti-dilutive shares">69,015,001</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zBYEntrvoee2" style="text-align: right" title="Anti-dilutive shares">18,818,413</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTXCbexcFgG5" style="text-align: right" title="Anti-dilutive shares">66,839,512</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Common stock issuable upon conversion of notes payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtMember_zcLB0uTz4J4a" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">14,461,844</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtMember_zXvF1rTmhQx4" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">18,397,839</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630_zZYlajo33HCf" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">105,742,503</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630_zDBfuNAXh9n6" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">154,252,352</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

72462246

69015001

18818413

66839512

14461844

18397839

105742503

154252352

Stock-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. Stock option grants, which are generally time or performance vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.

Research and Development Costs Research and development costs are expensed as incurred, and consist primarily of fees paid to consultants and outside service providers, and other expenses relating to the acquisition, design, development and testing of the Company’s products. Certain research and development activities are incurred under contract. In those instances, research and development costs are charged to operations ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s consolidated balance sheet and then charged to research and development costs in the Company’s consolidated statement of operations as those contract services are performed. For the six-month periods ended June 30, 2026 and 2025 research and development costs were $11,000 and $151,000, respectively.

11000

151000

Fair Value of Financial Instruments Accounting standards require certain assets and liabilities to be reported at fair value in the financial statements and provide a framework for establishing that fair value. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation techniques used to measure fair value: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if such data is available without undue cost and effort. The carrying amounts for cash, accounts payable, accrued expenses and convertible notes payable approximate their fair value due to the short-term nature of such instruments.

Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. At June 30, 2026 and December 31, 2025, the Company has determined that the warrants issued and outstanding meet the requirements for equity classification. This assessment, which requires the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all of the criteria for equity classification, the warrants are required to be liability-classified and recorded at their initial fair value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants that are liability-classified are recognized as a non-cash gain or loss in the statement of operations at each balance sheet date. At June 30, 2026 and December 31, 2025, the Company did not have any liability-classified warrants.

Recent Accounting Pronouncements In November 2024, the FASB issued ASU No. 2024-03 “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” This ASU requires public business entities to disclose, for interim and annual reporting periods, additional information about certain income statement expense categories. The requirements are effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027. Entities are permitted to apply either the prospective or retrospective transition methods. The Company is currently evaluating the impact that the adoption of this ASU will have on its consolidated financial statements. The Company’s management has evaluated all other the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Company’s financial position and results of operations.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">3.</td> <td style="text-align: justify">Accounts Payable and Accrued Expenses </td></tr> </table> As of June 30, 2026 and December 31, 2025, the Company owed $<span id="xdx_903_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20260630__srt--CounterpartyNameAxis__custom--FormerExecutiveMember__us-gaap--RelatedPartyTransactionAxis__custom--SeparationAgreementMember_zlBh4nRgheXl" title="Accounts payable and accrued expenses">197,000 and $<span id="xdx_902_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_pp0p0_c20251231__srt--CounterpartyNameAxis__custom--FormerExecutiveMember__us-gaap--RelatedPartyTransactionAxis__custom--SeparationAgreementMember_zqsPtpTQ9fxa" title="Accounts payable and accrued expenses">197,000, respectively, pursuant to a separation agreement with a former executive officer effective April 1, 2017 as amended by letter agreements dated effective August 16, 2018 and March 31, 2019, (the “Letter Agreements”) which have been included as part of accounts payable and accrued expenses on the accompanying condensed consolidated balance sheet. The payments are to be made at $10,000 per month. During the six months ended June 30, 2026 the Company made <span id="xdx_90E_eus-gaap--PaymentsForPostemploymentBenefits_pp0p0_do_c20260101__20260630__srt--CounterpartyNameAxis__custom--FormerExecutiveMember__us-gaap--RelatedPartyTransactionAxis__custom--SeparationAgreementMember_zFFoRjDnmwnb" title="Payment on separation agreement">no payments.

197000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">4.</td> <td style="text-align: justify">Convertible Notes Payable</td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ConvertibleDebtTableTextBlock_zsTW82FNWTp8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Notes Payable (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of convertible notes payable</td><td> </td> <td colspan="2" id="xdx_498_20260630_zHgVqoaahXMf" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_496_20251231_zyKjI6EiR901" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026 (unaudited)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleDebtCurrent_iI_maCzEzh_z197JBBkRHwc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Convertible notes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">609,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">822,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_maCzEzh_zDVchFyOgUM6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accrued interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">592,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">545,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_z1b77P5KaJd7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Total outstanding debt, including $1,201,000 and $1,116,000 in default at June 30, 2026 and December 31, 2025, respectively</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,201,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,367,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DebtInstrumentCarryingAmount_iNI_di0_zRxJIQMqHky8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible note discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayableCurrent_iI_zbSnNXHRrg84" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Balance on convertible notes, net of note discounts</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,201,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,351,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Convertible notes At December 31, 2025, total outstanding convertible notes payable totaled $822,000. During the six-month period ended June 30, 2026, the Company issued no convertible promissory notes. During the period ended June 30, 2026, convertible notes and accrued interest of $<span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20260101__20260630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zKuLC3Hu8bm4" title="Debt converted, amount converted">233,000, net of unamortized discount of $10,000, were converted into <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20260101__20260630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zLm5ymPzWxt4" title="Debt converted, shares issued">2,557,500 shares of common stock (see related accrued interest below). At June 30, 2026, total outstanding convertible notes payable totaled $609,000. As of June 30, 2026, convertible notes payable and accrued interest are convertible into approximately 14,461,844 shares of common stock at conversion rates ranging from $0.03 to $0.48 per share. As of June 30, 2026, a total of 46 convertible notes and accrued interest in the aggregate of $1,201,000 have reached maturity and are past due. Accrued interest At December 31, 2025, accrued interest on convertible notes payable totaled $545,000. During the six-month period ended June 30, 2026, accrued interest of $67,000 was recorded and accrued interest of $<span id="xdx_909_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20260101__20260630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TransactionTypeAxis__custom--InterestConvertedMember_zHlT9KvSVtR5" title="Accrued interest">22,000 was converted into <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pp0p0_c20260101__20260630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TransactionTypeAxis__custom--InterestConvertedMember_ztJZtWuHgig6" title="Converted shares">176,011 shares of common stock. At June 30, 2026, accrued interest on convertible notes payable totaled $592,000. Debt discount At December 31, 2025, the unamortized debt discount was $16,000. During the six-month period ended June 30, 2026, debt discount amortization of $6,000 was recorded, and $10,000 of debt discount was removed and included in the carrying amount of related convertible notes payable that were converted into shares of common stock. At June 30, 2026, the unamortized debt discount was $0.

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ConvertibleDebtTableTextBlock_zsTW82FNWTp8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Notes Payable (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of convertible notes payable</td><td> </td> <td colspan="2" id="xdx_498_20260630_zHgVqoaahXMf" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_496_20251231_zyKjI6EiR901" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026 (unaudited)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleDebtCurrent_iI_maCzEzh_z197JBBkRHwc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Convertible notes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">609,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">822,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_maCzEzh_zDVchFyOgUM6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accrued interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">592,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">545,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_z1b77P5KaJd7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Total outstanding debt, including $1,201,000 and $1,116,000 in default at June 30, 2026 and December 31, 2025, respectively</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,201,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,367,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DebtInstrumentCarryingAmount_iNI_di0_zRxJIQMqHky8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible note discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayableCurrent_iI_zbSnNXHRrg84" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Balance on convertible notes, net of note discounts</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,201,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,351,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

609000

822000

592000

545000

1201000

1116000

1201000

1367000

-0

16000

1201000

1351000

822000

233000

2557500

609000

1201000

545000

67000

22000

176011

592000

16000

6000

10000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">5.</td> <td style="text-align: justify">Research and Development</td></tr> </table> The Company constructs, develops and tests the AOT technologies with internal resources and through the assistance of various third-party entities. Costs incurred and expensed include fees such as license fees, purchase of test equipment, pipeline pumping equipment, crude oil tank batteries, viscometers, SCADA systems, computer equipment, payroll and other related equipment and various logistical expenses for the purposes of evaluating and testing the Company’s AOT prototypes. Costs incurred for research and development are expensed as incurred. Purchased materials that do not have an alternative future use are also expensed. Furthermore, costs incurred in the construction of prototypes with no certainty of any alternative future use and established commercial uses are also expensed. For the six-month periods ended June 30, 2026 and 2025, our research and development expenses were $11,000 and $151,000, respectively, including $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20260101__20260630__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--AOTPrototypesMember_zYHBgeDIN4bg" title="Research and development expenses">11,000 and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20250101__20250630__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--AOTPrototypesMember_zkajb7szKIM5" title="Research and development expenses">57,000 respectively, in the manufacture and testing of the AOT prototype equipment. Temple University Licensing Agreements-amount past due On August 1, 2011, the Company entered into two Exclusive License Agreements with Temple University (“Temple”). One license agreement covered technology to reduce crude oil viscosity (referred to as the “AOT-1 Agreement”) and the second license agreement covered technology associated with an electric and/or magnetic field assisted fuel injector system (referred to as the “AOT-2 Agreement”, and together with the AOT-1 Agreement, the “License Agreements”). The License Agreements provide the Company with exclusive, worldwide rights to Temple’s patents, patent applications, and technical information related to the respective technologies. Pursuant to the original terms of the License Agreements, the Company paid Temple a non-refundable license maintenance fee of $300,000 and agreed to pay (i) annual maintenance fees of $187,500, (ii) royalty fees ranging from 4% to 7% on net sales and extended term net sales, and (iii) 25% of all revenues generated from sublicenses. Effective as of September 26, 2025, the Company and Temple executed Amendment No. 2 to the AOT-1 Agreement and Amendment No. 1 to the AOT-2 Agreement, under which the Company and Temple agreed that total outstanding fees due to Temple through July 31, 2025, were $<span id="xdx_907_ecustom--TotalOutstandingFees_iI_c20250731__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--LicenseAgreementsMember__us-gaap--TransactionTypeAxis__custom--AOT1Amendment2Member_zV1Id9rPKrm" title="Total outstanding fees">2,236,000 and $<span id="xdx_909_ecustom--TotalOutstandingFees_iI_c20250731__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--LicenseAgreementsMember__us-gaap--TransactionTypeAxis__custom--AOT2Amendment1Member_zOBGmfLc6ULa" title="Total outstanding fees">931,000, respectively, for an aggregate amount of $<span id="xdx_90D_eus-gaap--AccountsPayableCurrent_iI_c20250731__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--LicenseAgreementsMember_zbTN82aOHq75" title="Accounts payable-license agreements - past due">3,167,000 (collectively, the “Outstanding Amounts”). The Outstanding Amounts were required to be paid by October 11, 2025. As of the date of this filing, the Outstanding Amounts have not been paid to Temple. As of June 30, 2026 and December 31, 2025, total unpaid fees due to Temple under the License Agreements amounted to $<span id="xdx_904_eus-gaap--AccountsPayableCurrent_iI_c20260630__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--LicenseAgreementsMember_zPnIDCI6lDi5" title="Accounts payable-license agreements - past due"><span id="xdx_905_eus-gaap--AccountsPayableCurrent_iI_c20251231__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--LicenseAgreementsMember_zAMl1oJAOFI6" title="Accounts payable-license agreements - past due">3,167,000, which are included in accounts payable – license agreements in the accompanying consolidated balance sheets. Under the amended agreements, royalty rates are structured as follows: 7% on the first $20 million of applicable net sales, 6% on sales between $20 million and $40 million, 5% on sales between $40 million and $100 million, and 4% on sales in excess of $100 million. These rates apply both during the initial term of the agreements and throughout the “Extended Term,” defined as a period of at least ten (10) years beginning upon the expiration of the last to expire patent (including continuations, extensions, and foreign counterparts), or upon early termination, whichever occurs earlier. During the Extended Term, royalties remain payable on all extended term net sales, regardless of patent expiration or the existence of valid claims. The amended agreements also clarified that the Company shall retain exclusive rights to any improvements developed solely by the Company during or after the Extended Term, and Temple shall have no ownership interest in such improvements. Notwithstanding this, the Company remains obligated to pay royalties on such sales during the Extended Term. The above description of the Temple Licensing Agreement Amendments is qualified in its entirety by reference to the amendments, copies of which were filed as exhibits to our report on Form 10-K, filed with the SEC on March 31, 2026. No revenues were recognized from these License Agreements during the period ended June 30, 2026, and 2025.

11000

151000

11000

57000

2236000 931000

3167000

Under the amended agreements, royalty rates are structured as follows: 7% on the first $20 million of applicable net sales, 6% on sales between $20 million and $40 million, 5% on sales between $40 million and $100 million, and 4% on sales in excess of $100 million. These rates apply both during the initial term of the agreements and throughout the “Extended Term,” defined as a period of at least ten (10) years

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">6.</td> <td style="text-align: justify">Common Stock</td></tr> </table> During the six months ended June 30, 2026, the Company issued 21,205,258 shares of its common stock as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px; text-align: justify">·</td> <td style="text-align: justify">The Company issued <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20260101__20260630__us-gaap--ConversionOfStockByUniqueDescriptionAxis__us-gaap--ConvertibleNotesPayableMember_zUnHr860Sdhe" title="Debt converted, shares issued">2,733,513, shares of its common stock upon the conversion of $<span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20260101__20260630__us-gaap--ConversionOfStockByUniqueDescriptionAxis__us-gaap--ConvertibleNotesPayableMember_zNStLff33Gz" title="Debt converted, amount converted">212,000 in convertible notes and $21,000 of accrued interest, net of unamortized discount of $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_pp0p0_c20260630__us-gaap--ConversionOfStockByUniqueDescriptionAxis__us-gaap--ConvertibleNotesPayableMember_zxF4oYSk1Sj7" title="Unamortized discount">0.10, pursuant to convertible notes with a conversion price of $<span id="xdx_908_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20260101__20260630__us-gaap--ConversionOfStockByUniqueDescriptionAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MinimumMember_zCJAk0i99Nji" title="Conversion price">0.08 to $<span id="xdx_90C_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20260101__20260630__us-gaap--ConversionOfStockByUniqueDescriptionAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MaximumMember_zhrUTyZklCme" title="Conversion price">0.15.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">The Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20260101__20260630__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ExerciseOfStockOptionsAndWarrantsMember_zlTcZCZXBWvh" title="Stock issued for options exercised, shares">14,071,747 shares of its common stock upon the exercise of stock options and warrants resulting in proceeds to the Company of $<span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20260101__20260630__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ExerciseOfStockOptionsAndWarrantsMember_zDn6OLKX6aBh" title="Debt converted, amount converted">1,342,000 based on conversion prices ranging from $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ExerciseOfStockOptionsAndWarrantsMember__srt--RangeAxis__srt--MinimumMember_zVv2XF0k2tth" title="Conversion price">0.03 to $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ExerciseOfStockOptionsAndWarrantsMember__srt--RangeAxis__srt--MaximumMember_zh42S5MwVAEf" title="Conversion price">0.10 per share.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">The Company issued <span id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20260101__20260630__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember_zMmnardd7jc9" title="Stock converted, shares issued">199,998 shares of its common stock upon the cashless exercise of warrants at $<span id="xdx_90E_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20260101__20260630__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember__srt--RangeAxis__srt--MinimumMember_zdhHY3zi6hH7" title="Conversion price">0.09 to $<span id="xdx_908_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20260101__20260630__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember__srt--RangeAxis__srt--MaximumMember_zCdDC3uGrmT2" title="Conversion price">0.16 per share for $<span id="xdx_907_eus-gaap--ConversionOfStockAmountConverted1_c20260101__20260630__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember_zpTjdOReGua3" title="Stock converted, amount converted">25,000, which were applied to the settlement of vendor accounts payable.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">The Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z6kVFOWyYoEi" title="Shares issued for services">3,450,000 shares of its common stock for services of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zHaQjD4hx3bh" title="Shares issued for services, value">345,000 valued at $0.10 per share.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">The Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zUIpyPKftdSh" title="Shares issued for compensation">750,000 shares of its common stock to an employee as compensation with a fair value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zExkxI4ZXv74" title="Shares issued for compensation, value">75,000.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> </table>

21205258

2733513

212000

21000

0.08

0.15

14071747

1342000

0.03

0.10

199998

0.09

0.16

25000

3450000

345000

0.10

750000

75000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">7.</td> <td style="text-align: justify">Stock Options and Warrants</td></tr> </table> The Company periodically issues stock options and warrants to employees and non-employees in capital raising transactions, for services, and for financing costs. Options Options vest according to the terms of the specific grant and expire from 2 to 10 years from date of grant. The weighted-average, remaining contractual life of employee and non-employee options outstanding at June 30, 2026 was 6.1 years. Stock option activity for the period January 1, 2026, up to June 30, 2026, was as follows: <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zVThwCh3WEYc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options and Warrants (Details - Options activity)"> <tr style="vertical-align: bottom"> <td>Schedule of stock option activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdcH1WBPjeZb" style="width: 13%; text-align: right" title="Options, Beginning balance">69,015,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2dgQVqQvst8" style="width: 13%; text-align: right" title="Weighted average exercise price, Beginning balance">0.07</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted (including 833,333 options granted to related parties)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCoptQn8BIA3" style="text-align: right" title="Options, Granted">6,733,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2pI74wp7xak" style="text-align: right" title="Weighted average exercise price, Granted">0.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zy6dYPgem8Db" style="text-align: right" title="Options, Exercised">(1,035,561</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zS32MCCiygi4" style="text-align: right" title="Weighted average exercise price, Exercised">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrvj86sGmg3f" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired">(2,250,527</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxAOmL5pGcVf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">0.19</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCZXYnnDcnde" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Ending balance">72,462,246</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zbemRqf5wxA1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Ending balance">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The weighted average exercise prices, remaining contractual lives for options granted, exercisable, and expected to vest as of June 30, 2026 were as follows: <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z6rR9Rgcv4P7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stock Options and Warrants (Details - Options by exercise price per share)"> <tr style="vertical-align: bottom"> <td style="text-align: center">Schedule of options per exercise price</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="8" style="border-bottom: black 1pt solid; text-align: center">Outstanding Options</td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Exercisable Options</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid"> Option Exercise Price Per Share</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 20%; text-align: center">$0.02 - $0.24</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zMmwz984DNPh" style="width: 13%; text-align: right" title="Shares, options outstanding">69,962,246</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: center"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z7HNROc8oLfk" title="Life (Years), options outstanding">6.3</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zBmRVBPe341d" style="width: 13%; text-align: right" title="Weighted average exercise price, options outstanding">0.06</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z8ofDWMigRp6" style="width: 13%; text-align: right" title="Shares, options exercisable">69,128,913</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zWlSD7xAil21" style="width: 13%; text-align: right" title="Weighted average exercise price, options exercisable">0.06</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center">$0.25 - $0.49</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhwGRfBHHkw9" style="border-bottom: black 1pt solid; text-align: right" title="Shares, options outstanding">2,500,000</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zKdkCxYgfUe5" title="Life (Years), options outstanding">0.8</td> <td> </td> <td>$</td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zPmYOGp0Ltb8" style="text-align: right" title="Weighted average exercise price, options outstanding">0.33</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zJcVT7uy6Mt8" style="border-bottom: black 1pt solid; text-align: right" title="Shares, options exercisable">2,500,000</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z5C72va4ony2" style="text-align: right" title="Weighted average exercise price, options exercisable">0.33</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="text-align: center"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2kemtDIMzn4" style="border-bottom: black 2.25pt double; text-align: right" title="Shares, options outstanding">72,462,246</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zIhteFaXf1i2" title="Life (Years), options outstanding">6.1</td> <td> </td> <td>$</td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJVWezBURQz1" style="text-align: right" title="Weighted average exercise price, options outstanding">0.07</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQlP3iqPt0th" style="border-bottom: black 2.25pt double; text-align: right" title="Shares, options exercisable">71,628,913</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zVqFlbTC6Bs3" style="text-align: right" title="Weighted average exercise price, options exercisable">0.07</td> <td> </td></tr> </table> As of June 30, 2026, the market price of the Company’s stock was $0.18 per share. At June 30, 2026, the aggregate intrinsic value of the options outstanding at June 30, 2026 was $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ziAfM94ffMA7" title="Options outstanding, intrinsic value">8,340,000. During the six month period ended June 30, 2026, options to acquire 1,035,561 shares of common stock were exercised resulting in proceeds to the Company of $39,000. Options issued to Officers and Directors In the six-month period ending June 30, 2026, the Company issued options to purchase <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zd693EZgJTmf" title="Options granted, shares">833,333 shares of common stock to members of the Board of Directors, including <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_z2iCDspg57af" title="Options granted, shares">500,000 options issued to the Company’s CEO/CFO pursuant to the Director Compensation Policy. <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zWHCSDYzGvh8" title="Options exercisable, shares">833,333 options are exercisable at $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zw5qEx20QBJe" title="Options exercisable, price per share">0.15 per share and vest over one year. Total fair value of these options at grant date was $<span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodValue_pp0p0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zcmiWeNnA6Lg" title="Fair value of options grant">125,000 using the Black-Scholes Option Pricing model with the following assumptions: expected life of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zHKhzb31xUR9" title="Options granted - expected term">5 years; risk free interest rate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zFyBGOEftm1" title="Options granted - risk-free interest rate">4.19%; volatility of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zpXewPXGBN3k" title="Assumptions used - volatility rate">189% and dividend yield of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zuKUvQWolSwi" title="Assumptions used - dividend rate">0%. During the six-month period ended June 30, 2026, the Company recognized compensation costs based on the fair value of options that vested of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--OfficersAndDirectorsMember_zRckTlb8KsNk" title="Share based compensation">62,000 to these officers and directors. Options issued for services In the six-month period ending June 30, 2026, the Company issued options to purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zZ6ZCWJTbG77" title="Options granted, shares">1,000,000 shares of common stock to its corporate secretary as compensation. The options are exercisable at a price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zOMEvkjb0Sng" title="Exercise price">0.10, fully vested, and expire <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zeXtL3eaPSO3" title="Options granted - expected term::XDX::P3Y">three years from the date of grant. Total fair value of these options at grant date was $<span id="xdx_90C_ecustom--FairValueOfOptionsGranted_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zDDfktULsi4d" title="Fair value of options granted">60,000 using the Black-Scholes Option Pricing model with the following assumptions: expected life of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zsJVY0SKvU8c" title="Options granted - expected term">1.5 years; risk free interest rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zEgRQuMPkO8" title="Options granted - risk-free interest rate">3.84%; volatility of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zP8FlYu7fc79" title="Assumptions used - volatility rate">144% and dividend yield of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zya6rNZz0mF3" title="Assumptions used - dividend rate">0%. During the six-month period ended June 30, 2026, the Company recognized compensation costs based on the fair value of options that vested of $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zvrIyzhTzkNd" title="Share based compensation">60,000. In the six-month period ending June 30, 2026, the Company issued options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember_z1TS6lu9JnSc" title="Options granted, shares">4,900,000 shares of common stock in exchange for services. The options are exercisable at prices ranging from $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember__srt--RangeAxis__srt--MinimumMember_zSRkyQuWWkPg" title="Exercise price">0.03 to $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember__srt--RangeAxis__srt--MaximumMember_zyH8UwoLefa2" title="Exercise price">0.10, were fully vested at date of grant, and expire three to <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember_zw4oyfHORBz" title="Options granted - expected term::XDX::P10Y">ten years from the date of grant. Total fair value of these options at grant date was $<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember_zDvt35zzwi4b" title="Fair value of options grant">412,000 using the Black-Scholes Option Pricing model with the following assumptions: expected life of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember__srt--RangeAxis__srt--MinimumMember_z3b4sNw0xobf" title="Options granted - expected term">3 to <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember__srt--RangeAxis__srt--MaximumMember_zwy2FxXFqI9k" title="Options granted - expected term">10 years; risk free interest rate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember__srt--RangeAxis__srt--MinimumMember_zjiefp6Cmv2i" title="Options granted - risk-free interest rate">3.84% to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember__srt--RangeAxis__srt--MaximumMember_zzjcAn93ziNa" title="Options granted - risk-free interest rate">4.53%; volatility of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember__srt--RangeAxis__srt--MinimumMember_zkSlQx6RMGHl" title="Assumptions used - volatility rate">144% to <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember__srt--RangeAxis__srt--MaximumMember_zfkclcYvDdFj" title="Assumptions used - volatility rate">179% and dividend yield of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember_zxy5dREzsgrf" title="Assumptions used - dividend rate">0%. During the six-month period ended June 30, 2026, the Company recognized compensation costs based on the fair value of options that vested of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember_zXaocUHo6Do3" title="Share based compensation">412,000. During the six-month period ended June 30, 2026 and 2025, the Company recognized compensation costs on the vested fair value of the option awards described above and on options granted in prior periods for an aggregate amount of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--VestedFairValueOfOptionsMember_z2hsBg7U6AMe" title="Share-based compensation expense">765,000 and $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember_zRX9yKJmK0Ab" title="Vested fair value of option">628,000, respectively. Warrants The following table summarizes certain information about the Company’s stock purchase warrants activity for the period starting January 1, 2026 up to June 30, 2026. <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zyFGY4hrS2Z1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options and Warrants (Details - Warrants activity)"> <tr style="vertical-align: bottom; background-color: White"> <td>Schedule of warrants activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNbWO7fLbMha" style="width: 13%; text-align: right" title="Warrants, beginning balance">45,622,728</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjPWAJBpZEe9" style="width: 13%; text-align: right" title="Weighted average exercise price, beginning balance">0.08</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJkaOC3QosCk" style="text-align: right" title="Warrants granted">5,199,998</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOiQt9GXMPr3" style="text-align: right" title="Weighted average exercise price, Granted">0.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z13MeYhqUyYd" style="text-align: right" title="Warrants exercised">(13,326,184</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKPagxFttpsc" style="text-align: right" title="Weighted average exercise price, Exercised">0.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJc2Jt07XaC9" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Expired">(18,768,129</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9jkNt2MATXb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">0.10</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFEBGJ9wweH4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, ending balance">18,818,413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zO2e9g9fpyl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance">0.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The weighted average exercise prices, remaining contractual lives for warrants granted, exercisable, and expected to vest as of June 30, 2026 were as follows: <table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockWarrantPlansByExercisePriceRangeTextBlock_zFC8ZCjnzfLg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stock Options and Warrants (Details - Warrants exercise price per share)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of warrants by exercise price</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="8" style="border-bottom: black 1pt solid; text-align: center">Outstanding Warrants</td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Exercisable Warrants</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: center">Warrant Exercise Price Per Share</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 22%; text-align: center">$0.02 - $0.24</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zuEBxQ0nuyb9" style="width: 13%; text-align: right">18,685,081</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: center"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zkhLdPRhiwjc" title="Life (Years), warrants outstanding">1.5</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zhEQE5LCcbn" style="width: 13%; text-align: right">0.06</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zEcIcpzddGvk" style="width: 13%; text-align: right">18,651,748</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zAthe9909dHg" style="width: 13%; text-align: right" title="Weighted average exercise price, warrants exercisable">0.06</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center">$0.25 - $0.49</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_zNFBcVseKpsh" style="border-bottom: black 1pt solid; text-align: right" title="Warrants outstanding">133,332</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_zIzfnL7qURo7" title="Life (Years), warrants outstanding">1.1</td> <td> </td> <td>$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_zXcoRoW5aPA5" style="text-align: right" title="Weighted average exercise price, warrants outstanding">0.28</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_d0_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_zEdCIjwKyNVf" style="border-bottom: black 1pt solid; text-align: right" title="Warrants exercisable">133,332</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_d0_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_zaZsG5HJr9b" style="text-align: right" title="Weighted average exercise price, warrants exercisable">0.28</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="text-align: right"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWmduHEEceoe" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding">18,818,413</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7FRbF3wQH83" title="Life (Years), warrants outstanding">1.5</td> <td> </td> <td>$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziHpyGIaDa68" style="text-align: right" title="Weighted average exercise price, warrants outstanding">0.06</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zHsqiWYiGfde" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants exercisable">18,785,080</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGTW22q93Q7e" style="text-align: right" title="Weighted average exercise price, warrants exercisable">0.06</td> <td> </td></tr> </table> At June 30, 2026, the market price of the Company’s common stock was $0.18 per share. At June 30, 2026, the aggregate intrinsic value of warrants outstanding was $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zo4hxCGd3Kkb" title="Aggregate intrinsic value of warrants outstanding">2,313,000 In the six-month period ending June 30, 2026, the Company issued warrants to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForServicesMember_zgAUqT6Y8iIe" title="Warrants granted">5,199,998 shares of common stock in exchange for services. The warrants are exercisable at a prices ranging from $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForServicesMember__srt--RangeAxis__srt--MinimumMember_zde2VvSr3pIc" title="Share based compensation exercise price range">0.09 to $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForServicesMember__srt--RangeAxis__srt--MaximumMember_zigUtc3VTFrk" title="Share based compensation exercise price range">0.12, vest up to one month from the date of grant, and expire two to <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember_zo4NqVApNJLc" title="Options granted - expected term::XDX::P3Y">three years from the date of grant. Total fair value of these warrants at grant date was $<span id="xdx_904_ecustom--FairValueOfWarrantsGranted_pp0p0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForServicesMember_zQiUE2hOBbM7" title="Fair value of warrants granted">462,000 using the Black-Scholes Option Pricing model with the following assumptions: life of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForServicesMember__srt--RangeAxis__srt--MinimumMember_zOvWn5C7kHld" title="Expected life">2 to <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForServicesMember__srt--RangeAxis__srt--MaximumMember_zlCVbxTPFgrl" title="Expected life">3 years; risk free interest rate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForServicesMember_zWDABjezgdLk" title="Risk free interest rate - minimum">3.48% to <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForServicesMember_zB7fALppgGU2" title="Risk free interest rate - maximum">4.21%; volatility of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForServicesMember_zkkyWOuQXnIl" title="Volatility - minimum">115% to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForServicesMember_zp043vQKbsbe" title="Volatility - maximum">141% and dividend yield of 0%. During the six-month period ended June 30, 2026, the Company recognized compensation costs based on the fair value of warrants that vested of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForServicesMember_zlaJzDAPZLB8" title="Share based compensation expense">463,000. During the period ended June 30, 2026, warrants to acquire 13,036,186 shares of common stock were exercised resulting in cash proceeds of $1,303,000 to the Company. In addition, <span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_c20260101__20260630__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember_zA5I0uw49Vqa" title="Stock converted, shares issued">199,998 shares were issued upon the cashless exercise of 199,998 warrants at $0.09 to $0.16 per share for $<span id="xdx_90B_ecustom--WarrantsExercisedValue_c20260101__20260630__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember_zNWgHrjW2vd1" title="Warrants exercised, value">25,000, which were applied to the settlement of vendor accounts payable.

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zVThwCh3WEYc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options and Warrants (Details - Options activity)"> <tr style="vertical-align: bottom"> <td>Schedule of stock option activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdcH1WBPjeZb" style="width: 13%; text-align: right" title="Options, Beginning balance">69,015,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2dgQVqQvst8" style="width: 13%; text-align: right" title="Weighted average exercise price, Beginning balance">0.07</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted (including 833,333 options granted to related parties)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCoptQn8BIA3" style="text-align: right" title="Options, Granted">6,733,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2pI74wp7xak" style="text-align: right" title="Weighted average exercise price, Granted">0.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zy6dYPgem8Db" style="text-align: right" title="Options, Exercised">(1,035,561</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zS32MCCiygi4" style="text-align: right" title="Weighted average exercise price, Exercised">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrvj86sGmg3f" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired">(2,250,527</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxAOmL5pGcVf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">0.19</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCZXYnnDcnde" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Ending balance">72,462,246</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zbemRqf5wxA1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Ending balance">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

69015001

0.07

6733333

0.10

1035561

0.04

2250527

0.19

72462246

0.07

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z6rR9Rgcv4P7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stock Options and Warrants (Details - Options by exercise price per share)"> <tr style="vertical-align: bottom"> <td style="text-align: center">Schedule of options per exercise price</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="8" style="border-bottom: black 1pt solid; text-align: center">Outstanding Options</td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Exercisable Options</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid"> Option Exercise Price Per Share</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 20%; text-align: center">$0.02 - $0.24</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zMmwz984DNPh" style="width: 13%; text-align: right" title="Shares, options outstanding">69,962,246</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: center"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z7HNROc8oLfk" title="Life (Years), options outstanding">6.3</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zBmRVBPe341d" style="width: 13%; text-align: right" title="Weighted average exercise price, options outstanding">0.06</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z8ofDWMigRp6" style="width: 13%; text-align: right" title="Shares, options exercisable">69,128,913</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zWlSD7xAil21" style="width: 13%; text-align: right" title="Weighted average exercise price, options exercisable">0.06</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center">$0.25 - $0.49</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhwGRfBHHkw9" style="border-bottom: black 1pt solid; text-align: right" title="Shares, options outstanding">2,500,000</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zKdkCxYgfUe5" title="Life (Years), options outstanding">0.8</td> <td> </td> <td>$</td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zPmYOGp0Ltb8" style="text-align: right" title="Weighted average exercise price, options outstanding">0.33</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zJcVT7uy6Mt8" style="border-bottom: black 1pt solid; text-align: right" title="Shares, options exercisable">2,500,000</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z5C72va4ony2" style="text-align: right" title="Weighted average exercise price, options exercisable">0.33</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="text-align: center"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2kemtDIMzn4" style="border-bottom: black 2.25pt double; text-align: right" title="Shares, options outstanding">72,462,246</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zIhteFaXf1i2" title="Life (Years), options outstanding">6.1</td> <td> </td> <td>$</td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJVWezBURQz1" style="text-align: right" title="Weighted average exercise price, options outstanding">0.07</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQlP3iqPt0th" style="border-bottom: black 2.25pt double; text-align: right" title="Shares, options exercisable">71,628,913</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zVqFlbTC6Bs3" style="text-align: right" title="Weighted average exercise price, options exercisable">0.07</td> <td> </td></tr> </table>

69962246

P6Y3M18D

0.06

69128913

0.06

2500000

P0Y9M18D

0.33

2500000

0.33

72462246

P6Y1M6D

0.07

71628913

0.07

8340000

1035561

39000

833333

500000

833333

0.15

125000

P5Y

0.0419

1.89

62000

1000000

0.10

60000

P1Y6M

0.0384

1.44

60000

4900000

0.03

0.10

412000

P3Y

P10Y

0.0384

0.0453

1.44

1.79

412000

765000

628000

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zyFGY4hrS2Z1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options and Warrants (Details - Warrants activity)"> <tr style="vertical-align: bottom; background-color: White"> <td>Schedule of warrants activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNbWO7fLbMha" style="width: 13%; text-align: right" title="Warrants, beginning balance">45,622,728</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjPWAJBpZEe9" style="width: 13%; text-align: right" title="Weighted average exercise price, beginning balance">0.08</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJkaOC3QosCk" style="text-align: right" title="Warrants granted">5,199,998</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOiQt9GXMPr3" style="text-align: right" title="Weighted average exercise price, Granted">0.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z13MeYhqUyYd" style="text-align: right" title="Warrants exercised">(13,326,184</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKPagxFttpsc" style="text-align: right" title="Weighted average exercise price, Exercised">0.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJc2Jt07XaC9" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Expired">(18,768,129</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9jkNt2MATXb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">0.10</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFEBGJ9wweH4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, ending balance">18,818,413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zO2e9g9fpyl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance">0.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

45622728

0.08

5199998

0.10

13326184

0.10

18768129

0.10

18818413

0.06

<table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockWarrantPlansByExercisePriceRangeTextBlock_zFC8ZCjnzfLg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stock Options and Warrants (Details - Warrants exercise price per share)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of warrants by exercise price</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="8" style="border-bottom: black 1pt solid; text-align: center">Outstanding Warrants</td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Exercisable Warrants</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: center">Warrant Exercise Price Per Share</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 22%; text-align: center">$0.02 - $0.24</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zuEBxQ0nuyb9" style="width: 13%; text-align: right">18,685,081</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: center"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zkhLdPRhiwjc" title="Life (Years), warrants outstanding">1.5</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zhEQE5LCcbn" style="width: 13%; text-align: right">0.06</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zEcIcpzddGvk" style="width: 13%; text-align: right">18,651,748</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zAthe9909dHg" style="width: 13%; text-align: right" title="Weighted average exercise price, warrants exercisable">0.06</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center">$0.25 - $0.49</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_zNFBcVseKpsh" style="border-bottom: black 1pt solid; text-align: right" title="Warrants outstanding">133,332</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_zIzfnL7qURo7" title="Life (Years), warrants outstanding">1.1</td> <td> </td> <td>$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_zXcoRoW5aPA5" style="text-align: right" title="Weighted average exercise price, warrants outstanding">0.28</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_d0_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_zEdCIjwKyNVf" style="border-bottom: black 1pt solid; text-align: right" title="Warrants exercisable">133,332</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_d0_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_zaZsG5HJr9b" style="text-align: right" title="Weighted average exercise price, warrants exercisable">0.28</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="text-align: right"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWmduHEEceoe" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding">18,818,413</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7FRbF3wQH83" title="Life (Years), warrants outstanding">1.5</td> <td> </td> <td>$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziHpyGIaDa68" style="text-align: right" title="Weighted average exercise price, warrants outstanding">0.06</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zHsqiWYiGfde" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants exercisable">18,785,080</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGTW22q93Q7e" style="text-align: right" title="Weighted average exercise price, warrants exercisable">0.06</td> <td> </td></tr> </table>

18685081

P1Y6M

0.06

18651748

0.06

133332

P1Y1M6D

0.28

133332

0.28

18818413

P1Y6M

0.06

18785080

0.06

0.18

2313000

5199998

0.09

0.12

462000

P2Y

P3Y

0.0348

0.0421

1.15

1.41

463000

13036186

1303000

199998

199998 25000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">8.</td> <td style="text-align: justify">Related Party Transactions</td></tr> </table> Employment Agreement with CEO/CFO On February 19, 2025, effective January 1, 2025, the Company entered into an employment agreement (the “Employment Agreement”) with Mr. Cecil Bond Kyte to serve as the Company’s CEO and CFO, with an annual base salary of $<span id="xdx_904_ecustom--AnnualBaseSalary_iI_pp0p0_c20250219__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember_zpqLRRpb2Ew7" title="Annual base salary">420,000. In addition, the Employment Agreement provides for the payment of a retention bonus (“Bonus”) in the amount of $<span id="xdx_909_ecustom--RetentionBonusPayable_iI_pp0p0_c20250131__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember_zJZfOsM82BSc" title="Retention bonus payable">1,557,500 to Mr. Kyte, $<span id="xdx_904_eus-gaap--LaborAndRelatedExpense_pp0p0_c20250103__20250131__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember_z3j6wCOYRPw6" title="Payment of retention bonus">519,167 of which was paid in January 2025 to Mr. Kyte on execution of the Employment Agreement; $519,167 of the Bonus was paid in part in May 2025 in anticipation of the execution of a customer contract with VIPS Petroleum, and the balance of that payment was paid in June and July 2025 to Mr. Kyte; and, $<span id="xdx_90A_ecustom--RetentionBonusToBePaid_iI_pp0p0_c20260630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember__us-gaap--TransactionTypeAxis__custom--ExecutionOfEquityFinancingMember_zGAcpOfehbWj" title="Retention bonus to be paid">519,166 of the Bonus will be paid to Mr. Kyte upon the execution, closing, and effective date of debt or equity financing in favor of the Company in the amount of no less than $5,000,000. As of June 30, 2026, certain payroll taxes of approximately $300,000 related to this bonus had not been remitted by either the employee or the Company to the applicable taxing authorities. Although these payroll taxes are the responsibility of the employee, the Company could become contingently liable in the event of nonpayment. As part of the Employment Agreement, Mr. Kyte was also issued in 2025 a stock option exercisable into <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zDboGBWWr2M9" title="Options granted, shares">20,817,500 shares of the Company’s restricted common stock at an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zttK5v55j2Q4" title="Exercise price">0.03 per share, and a stock option exercisable into <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStock2Member_zoyPQkEWW0Cl" title="Options granted, shares">3,500,000 shares of the Company’s restricted common stock at an exercise price of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStock2Member_zOQkj89TIBPc" title="Exercise price">0.03 per share. The stock options had a fair value of $<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember_zXbCa8VuEri8" title="Stock options fair value">3,614,000 and vested immediately and expire in ten years. Mr. Kyte was also issued stock options exercisable into <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zzGMW2k55oud" title="Restricted stock granted, shares">7,218,750 shares of the Company’s restricted stock with a fair value of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zSAAF7Zn6iE9" title="Restricted stock granted, value">1,072,000 in his capacity as a member of the Board of Directors and as a Chairman of the Board who oversees financial and audit functions, which vest up to one year, and have an exercise price of $0.02 to $0.15 per share. The above description of Mr. Kyte’s Employment Agreement is qualified in its entirety by reference to Mr. Kyte’s Employment Agreement, a copy of which was filed as part of our report on Form 8-K, filed with the SEC on February 21, 2025. During the six months ended June 30, 2026, Mr. Kyte received <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260630__srt--CounterpartyNameAxis__custom--KyteMember_zK1vPrq1dVqg" title="Options granted, shares">500,000 options with a fair value of $75,000 at an exercisable price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260630__srt--CounterpartyNameAxis__custom--KyteMember_z6zhhixhpAoj" title="Options granted, price per share">0.15 per share pursuant to the Company’s Director Compensation Policy which will vest over 1 year from issuance. (See Note 7, above.) Reimbursements for Rent The Company reimburses Mr. Kyte in rent expenses for a home office and partial storage space in Carson City, Nevada at a rate of $1,000 per month under a month-to-month rental agreement. The rental agreement ended on March 31, 2025. Under Mr. Kyte’s Employment Agreement, he receives a rent allowance of $1,000 per month, which is included as part of his compensation. Total rent expense during the six-month period ended June 30, 2026, and 2025 were $6,000 and $6,000, respectively which are included as part of operating expenses in the attached consolidated statement of operations.

420000 1557500

519167

519166

300000

20817500

0.03

3500000

0.03

3614000

7218750

1072000

500000

75000

0.15

6000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">9.</td> <td style="text-align: justify">Commitments and Contingencies</td></tr> </table> We may be involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. There is no current or pending litigation of any significance with the exception of the matters that have arisen under, and are being handled in, the normal course of business. At June 30, 2026 and 2025, the Company has recorded $197,000 related to certain contractually provided benefits to a former executive officer pursuant to a severance agreement. The former executive officer disputes the amount of $197,000, claiming the amount is less than the amount to which he believes he is owed. Absent an agreement to settle the dispute, and in the event the former executive officer elects to initiate litigation regarding the dispute, including claims for interest and penalties to which the former executive officer believes he is entitled, the Company has reserved, and if necessary and appropriate will assert, all factual and legal defenses, counter-claims, rights, and remedies it may have in any such suit. The Company believes it has recorded an appropriate accrual for the matter. Collaboration Agreement In 2024, the Company entered into a Collaboration Agreement with VIPS Petroleum, LLC (“VIPS”) to collaborate with them in facilitating the deployment of our AOT technology and products to VIPS’ customers. On June 25, 2025, the Company entered into a Distributor Agreement with VIPS, providing for VIPS to serve as our exclusive distributor to promote, sell, and lease our AOT product in the territories of Malaysia, Ghana, and India, among other territories. To date, we have not received any purchase orders under the Distributor Agreement, nor has our AOT product been placed with, nor currently being used by, any of VIPS’ customers or anyone else. The Distributor Agreement, as amended, provides that upon the Company’s receipt of payment for the purchase of two AOT Units, the Company shall issue VIPS/Stephen Bosco a stock purchase warrant exercisable into 25,000,000 restricted shares of the Company’s common stock, at a price of $0.07 cents per share (the “Exercise Price”). The warrant will vest on issuance and expire three years from the date of issuance. VIPS’ payment of the Exercise Price shall be rebate-based, meaning, for every AOT Unit sold by the Company to VIPS, the Company will process a post-sale rebate of 15% of the purchase price to VIPS. Post-sale rebates due VIPS, up to a maximum of $1,750,000, will be applied to, and be deemed payment of, the Exercise Price. To date, we have not received any purchase orders, nor generated any revenue, under the Distributor Agreement, as amended, nor has our AOT product been placed with, nor is it currently being used by, any of VIPS’ customers or anyone else, and we can provide no assurances that our AOT product will be accepted or purchased by VIPS, or any of its customers, or anyone else. As reported in our Form 10-K filed on March 31, 2026, the Company, together with VIPS and stakeholders identified under the VIPS Distributor Agreement, advanced the India potential commercialization pathway as reflected in the non-binding Laksel LOI.

197000

25000000

0.07

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">10.</td> <td style="text-align: justify">Segment Information</td></tr> </table> The Company operates and manages its business as one reportable and operating segment dedicated to the oil and gas industry. The measure of segment assets is reported on the balance sheet as total consolidated assets. In addition, the Company manages the business activities on a consolidated basis. The Company’s CODM reviews financial information presented on a consolidated basis and decides how to allocate resources based on consolidated net income (loss). Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM: <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z06viIeQEaO3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of significant segment expenses</td><td> </td> <td colspan="2" id="xdx_49B_20260401__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_zhHF1pczhc6a" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_z2IyLGkuE5yj" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--Revenues_d0_zE0rvdFGalnc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Revenue</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_iN_di_z4v96o7Btamj" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">(9,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">(104,000</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--EmployeeBenefitPayrollAndRelated_iN_pp0p0_di_z4Y8sF2fTgCl" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Payroll and related</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(185,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(816,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_iN_di_zSKQTzBNJIbc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,550,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(650,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--ConsultingRelatedToIntellectualProperty_iN_pp0p0_di_zDMmnr2MbcJ5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Consulting related to intellectual property</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(243,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(266,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--InsuranceRecoveries_iN_pp0p0_di_zd6UAuNWOVrj" style="vertical-align: bottom; background-color: White"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(71,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(24,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingExpenses_iN_pp0p0_di_zDeW7i69SFua" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(77,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(136,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--InterestExpenseOther_iN_pp0p0_di_zznJKU2LGwfb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(28,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(143,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,163,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,139,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_491_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_zXuXMEfySrsa" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_496_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_zwkjnhswGUUh" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--Revenues_d0_zy9BWi2u9Lcl" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Revenue</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_iN_di_zrO1Va0mcxc8" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">(11,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">(151,000</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--EmployeeBenefitPayrollAndRelated_iN_pp0p0_di_zf0gZk6vBaI7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Payroll and related</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(365,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,492,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_iN_di_zjFvpyP6BXij" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,735,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,942,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--ConsultingRelatedToIntellectualProperty_iN_pp0p0_di_zWVw97FsjDn9" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Consulting related to intellectual property</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(453,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(591,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--InsuranceRecoveries_iN_pp0p0_di_zT2J8nfkJc5h" style="vertical-align: bottom; background-color: White"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(146,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(43,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpenses_iN_pp0p0_di_zU9K07v0RGPd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(161,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(336,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--InterestExpenseOther_iN_pp0p0_di_zbvQkdihyFli" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(73,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(258,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLoss_zp9rHk6fOLib" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,944,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,813,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z06viIeQEaO3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of significant segment expenses</td><td> </td> <td colspan="2" id="xdx_49B_20260401__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_zhHF1pczhc6a" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_z2IyLGkuE5yj" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--Revenues_d0_zE0rvdFGalnc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Revenue</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_iN_di_z4v96o7Btamj" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">(9,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">(104,000</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--EmployeeBenefitPayrollAndRelated_iN_pp0p0_di_z4Y8sF2fTgCl" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Payroll and related</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(185,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(816,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_iN_di_zSKQTzBNJIbc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,550,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(650,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--ConsultingRelatedToIntellectualProperty_iN_pp0p0_di_zDMmnr2MbcJ5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Consulting related to intellectual property</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(243,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(266,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--InsuranceRecoveries_iN_pp0p0_di_zd6UAuNWOVrj" style="vertical-align: bottom; background-color: White"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(71,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(24,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingExpenses_iN_pp0p0_di_zDeW7i69SFua" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(77,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(136,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--InterestExpenseOther_iN_pp0p0_di_zznJKU2LGwfb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(28,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(143,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,163,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,139,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_491_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_zXuXMEfySrsa" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_496_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_zwkjnhswGUUh" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--Revenues_d0_zy9BWi2u9Lcl" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Revenue</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_iN_di_zrO1Va0mcxc8" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">(11,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">(151,000</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--EmployeeBenefitPayrollAndRelated_iN_pp0p0_di_zf0gZk6vBaI7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Payroll and related</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(365,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,492,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_iN_di_zjFvpyP6BXij" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,735,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,942,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--ConsultingRelatedToIntellectualProperty_iN_pp0p0_di_zWVw97FsjDn9" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Consulting related to intellectual property</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(453,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(591,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--InsuranceRecoveries_iN_pp0p0_di_zT2J8nfkJc5h" style="vertical-align: bottom; background-color: White"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(146,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(43,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpenses_iN_pp0p0_di_zU9K07v0RGPd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(161,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(336,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--InterestExpenseOther_iN_pp0p0_di_zbvQkdihyFli" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(73,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(258,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLoss_zp9rHk6fOLib" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,944,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,813,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

9000

104000

185000 816000

1550000

650000

243000 266000

71000

24000

77000

136000

28000

143000

-2163000

-2139000

11000

151000

365000 1492000

1735000

8942000

453000 591000

146000

43000

161000

336000

73000

258000

-2944000

-11813000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">11.</td> <td style="text-align: justify">Subsequent Events</td></tr> </table> In July 2026, the Company issued 750,000 shares of its common stock upon the exercise of warrants for proceeds of $75,000 at an exercise price of $0.10 per share.

false false false false